Annex to the GLG report: Estimating the return on investment from tackling antimicrobial resistance using a package of One Health interventions

Overview

• It will be met with significantly higher healthcare costs, with annual expenses for treating resistant bacterial infections estimated to reach US$ 412 billion worldwide.
• The increase in morbidity and mortality resulting from these bacterial infections will impose economic losses of US$ 443 billion from reduced workforce productivity alone.
• Evaluation of a mixed policy of One Health interventions – including awareness raising, surveillance, optimizing antimicrobial use in human and animal health, infection prevention, and new treatments – suggests a potential to avert nearly US$ 7.7 trillion in losses deriving from healthcare expenditure and workforce productivity by 2035. Implemented for longer, these interventions would offset another US$ 615.5 billion in losses per year, resulting in cumulative gains of US$ 19.1 trillion by 2050.
• The One Health intervention package considered in this study is estimated to cost US$ 1,248.1 billion worldwide by 2050, or US$ 40.3 billion per year.
• From this perspective in which the economic impact from AMR is measured through changes in healthcare expenditure and general workforce productivity, for every US$ 1 invested in a mixed policy intervention package, a global net return of between US$ 10.9 and US$ 14.2 is expected (2035 and 2050 scenarios respectively).